Overview A Study of Sodium Oligomannate (GV-971) in Participants With Mild to Moderate Alzheimer's Disease Status: Recruiting Trial end date: 2026-10-01 Target enrollment: Participant gender: Summary The purpose of this study is to evaluate the safety, tolerability and efficacy of GV-971 in mild to moderate Alzheimer's disease. Phase: Phase 3 Details Lead Sponsor: Shanghai Greenvalley Pharmaceutical Co., Ltd.